Literature DB >> 29700601

Attitude towards ovarian tissue and oocyte cryopreservation for non-medical reasons: a cross-sectional study.

Nada Woodtli1, Michael von Wolff1, Norman Bitterlich2, Petra Stute3,4.   

Abstract

PURPOSE: To assess the attitude towards ovarian tissue and oocyte cryopreservation for non-medical reasons.
METHODS: Cross-sectional electronic survey in 248 Swiss women aged 15-35 years, nationally representative for educational level.
RESULTS: Most women did not worry about an age-related fertility decline. Two-thirds of women would consider using hormone therapy (HT) for menopausal symptom relief although concerns about side effects and risks were still high. Acceptance of cryopreservation of oocytes (19%) or ovarian tissue (13%) for postponing fertility or menopause was generally low, but increased (37%) if both goals could be achieved with one surgery. Cryopreservation of ovarian tissue for postponing menopause was acceptable for 22% of women. Not having a suitable partner until age 35 increased the likelihood of considering postponing fertility by cryopreservation (p < 0.001) and had a stronger impact on that decision than the factor "pursuing a career" (p < 0.001).
CONCLUSION: More education on age-related fertility decline, menopause and HT (benefit-risk ratio) is needed. Furthermore, the political and socioeconomic discussion should focus on women's needs, especially on compatibility of career and family.

Entities:  

Keywords:  Cryopreservation; Fertility; Hormone therapy; Oocyte; Ovarian tissue

Mesh:

Year:  2018        PMID: 29700601     DOI: 10.1007/s00404-018-4778-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Stepped vitrification technique for human ovarian tissue cryopreservation.

Authors:  Ellen Cristina Rivas Leonel; Ariadna Corral; Ramon Risco; Alessandra Camboni; Sebastião Roberto Taboga; Peter Kilbride; Marina Vazquez; John Morris; Marie-Madeleine Dolmans; Christiani A Amorim
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.